Company Overview of Philogen S.p.A.
Philogen S.p.A. is a biopharmaceutical company that targets cancer and other angiogenesis-associated diseases. It engages in developing immunocytokines, antibodies, and vascular targeting drugs; the discovery, GMP production, and clinical development of immunomodulatory biopharmaceuticals; developing antibody-based therapeutics specific for markers of angiogenesis; and developing DNA-encoded chemical libraries, small molecule drug conjugates, and antibody drug conjugates. It develops DARLEUKIN (L19-IL2), an immunostimulatory compound; TELEUKIN (F16-IL2), a human immunostimulatory antibody; FIBROMUN (L19-TNF), an anti-EDB human antibody; RADRETUMAB (L19-131I), a human vascular targeting antib...
Via Bellaria, 35
Sovicille, SI 53018
Founded in 1996
Key Executives for Philogen S.p.A.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Director of IP & Licensing and Director
Co-Founder, President of the Scientific Advisory Board and Director
Vice President and Director
Compensation as of Fiscal Year 2015.
Philogen S.p.A. Key Developments
Pfizer Exercises Options Under Antibodies Agreement with Philogen
Jan 22 16
Philogen SpA announced that Pfizer Inc. had exercised options granting exclusive rights on the development of certain antibody drug conjugates (ADCs) under an agreement signed in December 2014. Pfizer will also oversee the research and development of candidate molecules, as well as their potential marketing. In December 2014 Philogen and Pfizer signed a licence and option agreement to develop novel ADC technology based on Philogen validated antibodies.
Philogen S.p.A. Announces Commencement of Phase III Pivotal Trial in Melanoma
Jan 21 16
Philogen S.p.A. announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach. Stage IIIB/C melanoma patients are at high-risk of progression to the aggressive Stage IV of the disease, which is in most cases fatal. Surgery is the first therapeutic option in Stage IIIB/C patients, and is performed with a curative intent. However, unfortunately, most patients undergo further recurrences of disease and surgery becomes no longer feasible. Therefore the ability to eradicate metastatic lesions, using a biotherapeutic approach which provides a protective anti-cancer immunity, would offer an opportunity to prevent progression and prolong survival. In a recently published Phase II clinical trial, the Philogen group and collaborating Clinical Centers have demonstrated that the intratumoral injection of a combination of two immunocytokines (L19-IL2 and L19-TNFï¡) is able to substantially reduce or eradicate injected melanoma lesions, with durable responses and excellent cosmetic results. In addition, there was evidence of systemic bystander effects on non-injected lesions, indicating the onset of a protective anti-cancer immunity. These data reinforce the findings of a previous Phase II clinical trial and of extensive preclinical investigations.
Boehringer Ingelheim, Philogen to Co-Develop Myeloid Leukaemia Treatments
Oct 13 15
Boehringer Ingelheim announced that it will collaborate with Philogen on the development of novel treatments for acute myeloid leukaemia. No financial terms were disclosed. Under their cooperation agreement, the companies will test "novel immunotherapy concepts" in one trial.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|